Lupin plans to launch 3-4 generic drugs in U.S. by end-March

MUMBAI Thu Jan 31, 2013 3:06pm IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Lupin Ltd(LUPN.NS), India's fourth largest drugmaker by sales, expects to launch three to four new generic drugs in its key U.S. market by March end, its Group President Nilesh Gupta said on Thursday.

The Mumbai-based drugmaker has so far launched six products in this fiscal year in the United States, which generates about 42 percent of its total formulation sales.

The drugmaker earlier reported a forecast-beating 42.6 percent rise in quarterly net profit to 3.35 billion rupees.

(Reporting by Kaustubh Kulkarni; Editing by Anand Basu)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

India Economy

REUTERS SHOWCASE

Reliance Projects

Reliance Projects

Exclusive: Reliance plans $13 billion projects including new refinery.  Full Article 

Pharma Sector

Pharma Sector

In race for bigger margins, drug makers willing to lose the India "advantage".  Full Article 

Low Stocks

Low Stocks

Indian power station coal stocks lowest since 2012 blackouts.  Full Article 

Markets This Month

Markets This Month

Tata Motors, M&M top Sensex gainers  Full Article 

Google Drones

Google Drones

Google is testing unmanned drones to deliver anything from dog food to medicine.  Video 

#RiceBucketChallenge

#RiceBucketChallenge

In India, rice replaces ice in bucket challenge.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage